Investor Kit

Information for Informed Investment Decisions

Verastem Oncology, Inc. (NASDAQ: VSTM), is a biopharmaceutical company headquartered in Needham, MA. The focus of our research is developing a portfolio of novel small molecule drugs that inhibit critical RAS signaling pathways that promote cancer cell survival and tumor growth.


To learn more about our research program, as well as the details of our financials, please download the investor kits below. Verastem Oncology is a member of NASDAQ Biotechnology Index.

Corporate Presentation

Well Positioned to Capitalize on Growth Opportunities

Corporate Latest 10-K

Annual Report for the Fiscal Year Ending December 31, 2022

Corporate Proxy Statement

Proxy Statement for Annual Meeting of Stockholders Held May 15, 2023

Investor Contact

Dan Calkins
Investor Relations
+1 781.469.1694


Ryan Porter
Argot Partners
+1 212.600.1902